Oncotype DX Prostate Recurrence Score

The Oncotype DX^® Prostate Cancer Assay provides men with newly diagnosed, low-risk prostate cancer and their urologists, critical information to help guide decisions about treatment.

The Oncotype DX Prostate Cancer Assay examines specific genes from a patient’s prostate tumour biopsy, providing individualised information on the biology of their tumour. The activity of these genes influences and regulates the behaviour of the tumour, including whether or not the cancer is likely to grow and spread.

The Oncotype DX Prostate Cancer Assay reports a patient’s Genomic Prostate Score (GPS). The GPS provides important information about how aggressive the cancer is. Used along with other test results, the GPS can help personalise a treatment plan.

The information in the Oncotype DX Prostate Cancer Assay report provides a greater level of confidence when deciding whether to choose active surveillance or to begin immediate treatment with surgery or radiation.

Oncotype DX^® and Recurrence Score^® are registered trademarks of Genomic Health, Inc. Oncotype DX^® is under license from Genomic Health Inc.